Jefferies Group’s Sutro Biopharma STRO Stock Holding History

Jefferies Group’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,350	Closed	-$498K	–	1920
2021 Q4	$498K	Buy	+3,350	New	+$600K	﹤0.01%	1177

Other funds holding STRO

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Jefferies Group's STRO Position: Q1 2022 in Review

Jefferies Group sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 340 shares — an estimated $50.6K sold.

Jefferies Group first reported a position in STRO in Q3 2020 and held it in 2 quarters. The position peaked at $260K in Q3 2020. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

Jefferies Group reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 340 Sutro Biopharma shares in Q1 2022, an estimated $50.6K.
Jefferies Group first reported a position in Sutro Biopharma in Q3 2020 and held it in 2 quarters.
Jefferies Group's Sutro Biopharma position peaked at $260K in Q3 2020.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.